Depression clinical trials
312 active trials name this condition (recorded in the registry as “Unipolar Depression”) . Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
- Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS
- Mindfulness-based Psilocybin Therapy for PTSD
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
- Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- Stratified Pharmacological Approaches for Regulating Circuit-Level Effects
- A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Mechanisms Of Orbitofrontal Stimulation in Depression
- A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- tDCS: Sleep to Mood in Depression (S2M-D)
- Mindfulness Engaged Neurostimulation for Depression (MEND II)
- NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Ketamine Alcohol (in Treatment-Resistant Depression)
- Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients
- A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- Maintenance rTMS for Depression (Maitr-De)
- Peer-Delivered Behavioral Activation in a CCBHC
- Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk
- Nutritional Intervention for College Students With Depression
- ALTO-100 in Bipolar Disorder With Depression (BD-D)
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
- ALTO-207 in Adults With Treatment-resistant Depression (TRD)
- Leucine in Midlife Depression
- Neurofeedback to Treat Depression - 2
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
- Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
- Exercise-priming of CBT for Depression: the CBT+ Trial
- PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
- Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
- Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
- Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality
- Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
- A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Investigation to Understand and Optimize Psilocybin
- Closed-Loop Deep Brain Stimulation for Major Depression
- Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
- Enhancing Slow Wave Sleep in Depression
- Dosing rTMS for Depression Post-SCI
- Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Aβ Dynamics in LLMD
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Unipolar Depression” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.